---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-21-022654"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2021-09-27T23:59:59+00:00"
generated_at: "2026-06-29T01:15:00.743050+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# DiaMedica raises $30M in private placement at $3.92/share for DM199 development

## Summary
- Gross proceeds of $30M from sale of 7,653,060 common shares at $3.92 each.
- Closing expected September 28, 2021; net proceeds to fund DM199 clinical development including ReMEDy2 trial.
- Ten accredited investors participate; shares unregistered but resale registration to be filed with SEC.
- Funds also allocated to working capital and general corporate purposes.

## SEC filing metadata
- accession: 0001437749-21-022654
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2021-09-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774921022654/0001437749-21-022654-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774921022654/dmtp20210926_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-21-022654
- JSON: https://secwatch.observer/filing/0001437749-21-022654.json
- Plain text: https://secwatch.observer/filing/0001437749-21-022654.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.